NARI - Inari Medical Inc. (NARI) Q1 2024 Earnings Call Transcript
2024-05-01 03:32:02 ET
Inari Medical, Inc. (NARI)
Q1 2024 Earnings Conference Call
April 30, 2024, 16:30 PM ET
Company Participants
John Hsu - Vice President, Investor Relations
Drew Hykes - Chief Executive Officer
Mitch Hill - Chief Financial Officer
Tom Tu - Chief Medical Officer
Conference Call Participants
Stephanie Piazzola - Bank of America
Marie Thibault - BTIG
Kallum Titchmarsh - Morgan Stanley
William Plovanic - Canaccord
Chris Pasquale - Nephron Research
David Rescott - Baird
Michael Sarcone - Jefferies
Adam Maeder - Piper Sandler
Richard Newitter - Truist Securities
Presentation
Operator
Good day, ladies and gentlemen. And welcome to Inari Medical Inc. First Quarter 2024 Earnings Conference Call. All participants are in a listen-only mode. At the end of the company's prepared remarks, we will conduct a question-and-answer session. As a reminder, this call is being recorded and will be available on the company's website for replay shortly.
I’d now like to turn the conference over to John Hsu, VP Investor Relations. Please go ahead.
John Hsu
Thank you, operator. Welcome to Inari's conference call to discuss our first quarter 2024 financial performance.
Joining me on today's call are Drew Hykes, President and Chief Executive Officer; and Mitch Hill, Chief Financial Officer. This call includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements made on this call that do not relate to matters of historical facts should be considered forward-looking statements, including statements related to Inari's estimated full year 2024 revenue, operating loss or profitability expectations, and the expected operating performance and potential strategic benefits of LimFlow. These statements are based on Inari's current expectations, forecasts, and assumptions, which are subject to inherent uncertainties, risks, and assumptions that are difficult to predict.
Actual outcomes and results could differ materially from any results, performance or achievements expressed or implied by the forward-looking statements due to several factors. Please review Inari's most recent filings with the SEC, particularly the risk factors described in our latest Form 10-K for additional information. Any forward-looking statements provided during this call, including projections for future performance, are based on management's expectations as of today. Inari undertakes no obligation to update these statements, except as required by applicable law.
On today's call, we will refer to both GAAP and non-GAAP financial measures in announcing our Q1 2024 results. Please refer to today's press release for reconciliation of the non-GAAP measures discussed on this call and referred to in the press release. The press release and the slides accompanying this call are available on our website at inarimedical.com. A recording of today's call will be available on our website by 5:00 p.m. Pacific time today....
Inari Medical, Inc. (NARI) Q1 2024 Earnings Call Transcript